RYTM vs. ARVN, MORF, AKRO, PLRX, ANNX, ROIV, ELAN, ASND, LEGN, and CERE
Should you be buying Rhythm Pharmaceuticals stock or one of its competitors? The main competitors of Rhythm Pharmaceuticals include Arvinas (ARVN), Morphic (MORF), Akero Therapeutics (AKRO), Pliant Therapeutics (PLRX), Annexon (ANNX), Roivant Sciences (ROIV), Elanco Animal Health (ELAN), Ascendis Pharma A/S (ASND), Legend Biotech (LEGN), and Cerevel Therapeutics (CERE). These companies are all part of the "pharmaceutical preparations" industry.
Rhythm Pharmaceuticals (NASDAQ:RYTM) and Arvinas (NASDAQ:ARVN) are both mid-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, analyst recommendations, earnings, profitability, dividends, valuation and community ranking.
Rhythm Pharmaceuticals has a beta of 1.94, indicating that its stock price is 94% more volatile than the S&P 500. Comparatively, Arvinas has a beta of 1.95, indicating that its stock price is 95% more volatile than the S&P 500.
Rhythm Pharmaceuticals received 104 more outperform votes than Arvinas when rated by MarketBeat users. Likewise, 65.71% of users gave Rhythm Pharmaceuticals an outperform vote while only 65.40% of users gave Arvinas an outperform vote.
Rhythm Pharmaceuticals has higher earnings, but lower revenue than Arvinas. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Arvinas, indicating that it is currently the more affordable of the two stocks.
Rhythm Pharmaceuticals presently has a consensus target price of $54.33, indicating a potential upside of 52.28%. Arvinas has a consensus target price of $61.13, indicating a potential upside of 84.47%. Given Arvinas' stronger consensus rating and higher possible upside, analysts clearly believe Arvinas is more favorable than Rhythm Pharmaceuticals.
In the previous week, Rhythm Pharmaceuticals and Rhythm Pharmaceuticals both had 5 articles in the media. Arvinas' average media sentiment score of 1.58 beat Rhythm Pharmaceuticals' score of 0.59 indicating that Arvinas is being referred to more favorably in the news media.
Arvinas has a net margin of -185.09% compared to Rhythm Pharmaceuticals' net margin of -297.91%. Arvinas' return on equity of -64.79% beat Rhythm Pharmaceuticals' return on equity.
95.2% of Arvinas shares are owned by institutional investors. 5.6% of Rhythm Pharmaceuticals shares are owned by company insiders. Comparatively, 5.2% of Arvinas shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Summary
Arvinas beats Rhythm Pharmaceuticals on 12 of the 17 factors compared between the two stocks.
Get Rhythm Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for RYTM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RYTM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Rhythm Pharmaceuticals Competitors List
Related Companies and Tools
